Literature DB >> 11435453

Immunomodulatory therapy of human type 1 diabetes: lessons from the mouse.

J P Palmer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11435453      PMCID： PMC209348          DOI： 10.1172/JCI13445

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  20 in total

1.  The NOD mouse model of type 1 diabetes: as good as it gets?

Authors:  M A Atkinson; E H Leiter
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

2.  Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.

Authors:  T Kobayashi; K Nakanishi; T Murase; K Kosaka
Journal:  Diabetes       Date:  1996-05       Impact factor: 9.461

3.  Immunological and metabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM.

Authors:  M A Bowman; L Campbell; B L Darrow; T M Ellis; A Suresh; M A Atkinson
Journal:  Diabetes       Date:  1996-02       Impact factor: 9.461

4.  Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons.

Authors:  D K McCulloch; D J Koerker; S E Kahn; S Bonner-Weir; J P Palmer
Journal:  Diabetes       Date:  1991-06       Impact factor: 9.461

5.  Functional state of the beta cell affects expression of both forms of glutamic acid decarboxylase.

Authors:  W Hao; L Li; V Mehta; A Lernmark; J P Palmer
Journal:  Pancreas       Date:  1994-09       Impact factor: 3.327

Review 6.  Lessons learned from use of cyclosporine for insulin-dependent diabetes mellitus. The case for immunotherapy for insulin-dependent diabetics having residual insulin secretion.

Authors:  J L Mahon; J Dupre; C R Stiller
Journal:  Ann N Y Acad Sci       Date:  1993-11-30       Impact factor: 5.691

7.  The functional state of the beta cell modulates IL-1 and TNF-induced cytotoxicity.

Authors:  V Mehta; W Hao; B M Brooks-Worrell; J P Palmer
Journal:  Lymphokine Cytokine Res       Date:  1993-08

8.  Insulin prophylaxis in individuals at high risk of type I diabetes.

Authors:  R J Keller; G S Eisenbarth; R A Jackson
Journal:  Lancet       Date:  1993-04-10       Impact factor: 79.321

9.  Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  1987-07       Impact factor: 5.958

10.  Role of infiltrating T cells for impaired glucose metabolism in pancreatic islets isolated from non-obese diabetic mice.

Authors:  E Strandell; S Sandler; C Boitard; D L Eizirik
Journal:  Diabetologia       Date:  1992-10       Impact factor: 10.122
View more
  3 in total

Review 1.  Latent autoimmune diabetes in adults (LADA).

Authors:  Ramachandra G Naik; Jerry P Palmer
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

2.  Limited effect of CpG ODN in preventing type 1 diabetes in NOD mice.

Authors:  Byong Jun Lee; Soo Kie Kim; Moon Kyu Kim; Eon Sub Park; Hyun Chul Cho; Myung Sook Shim; Mi Jin Kim; Young Goo Shin; Choon Hee Chung
Journal:  Yonsei Med J       Date:  2005-06-30       Impact factor: 2.759

3.  Designed Functional Dispersion for Insulin Protection from Pepsin Degradation and Skeletal Muscle Cell Proliferation: In Silico and In Vitro Study.

Authors:  Veera C S R Chittepu; Poonam Kalhotra; Tzayhri Gallardo-Velázquez; Raúl René Robles-de la Torre; Guillermo Osorio-Revilla
Journal:  Nanomaterials (Basel)       Date:  2018-10-19       Impact factor: 5.076
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.